Payment overview · 2025
General Payments
$396.60
23 reported records · 6 companies
Healthcare provider profile · identity verified
Robert Lee Allman, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PENDLETON, SC · NPI 1376804658
Verified facts
What the public records show
CMS Open Payments records show Robert Lee Allman, M.D. received $396.60 in general payments during 2025 across 23 reported records.
Novo Nordisk Inc accounted for 38.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $153.14 | 38.6% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $88.38 | 22.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.75 | 12.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $43.88 | 11.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.61 | 8.2% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $30.84 | 7.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $396.60 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $125.83 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $107.39 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.75 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.75 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.80 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $46.80 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $41.58 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $30.84 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.09 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.31 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 139 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 152 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
152 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
139 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 469 | 125 |
| Lisinopril | Lisinopril | 389 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 344 | 88 |
| Losartan Potassium | Losartan Potassium | 294 | 73 |
| Gabapentin | Gabapentin | 272 | 60 |
| Trazodone Hcl | Trazodone Hcl | 270 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 262 | 73 |
| Alprazolam | Alprazolam | 233 | 34 |
| Metformin Hcl | Metformin Hcl | 228 | 63 |
| Omeprazole | Omeprazole | 225 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 222 | 54 |
| Simvastatin | Simvastatin | 173 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 170 | 48 |
| Meloxicam | Meloxicam | 169 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 153 | 25 |
| Ozempic | Semaglutide | 152 | 29 |
| Eliquis | Apixaban | 139 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 138 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 136 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 136 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 36 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 120 | 29 |
| Glipizide | Glipizide | 117 | 30 |
| Carvedilol | Carvedilol | 115 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 28 |
| Tramadol Hcl | Tramadol Hcl | 107 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 42 |
| Sertraline Hcl | Sertraline Hcl | 102 | 20 |
| Prednisone | Prednisone | 101 | 74 |
| Bupropion Xl | Bupropion Hcl | 100 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 99 | 19 |
| Clonazepam | Clonazepam | 98 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 23 |
| Lorazepam | Lorazepam | 89 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 83 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 30 |
| Allopurinol | Allopurinol | 82 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 78 | 28 |
| Montelukast Sodium | Montelukast Sodium | 76 | 23 |
| Nifedipine Er | Nifedipine | 74 | 18 |
| Metformin Hcl Er | Metformin Hcl | 72 | 19 |
| Buspirone Hcl | Buspirone Hcl | 71 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 20 |
| Furosemide | Furosemide | 67 | 24 |
| Atenolol | Atenolol | 66 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 19 |
| Valsartan | Valsartan | 65 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 13 |
| Pregabalin | Pregabalin | 61 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 26 |
| Ipratropium Bromide | Ipratropium Bromide | 60 | 41 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 12 |
| Famotidine | Famotidine | 55 | 19 |
| Mounjaro | Tirzepatide | 52 | suppressed |
| Ondansetron Odt | Ondansetron | 51 | 21 |
| Celecoxib | Celecoxib | 50 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 37 |
| Sumatriptan Succinate | Sumatriptan Succinate | 46 | suppressed |
| Finasteride | Finasteride | 45 | 12 |
| Azithromycin | Azithromycin | 44 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Glimepiride | Glimepiride | 40 | suppressed |
| Potassium Chloride | Potassium Chloride | 39 | 11 |
| Glipizide Er | Glipizide | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 18 |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 13 |
| Valacyclovir | Valacyclovir Hcl | 34 | 16 |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 23 |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 16 |
| Fluconazole | Fluconazole | 22 | 20 |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $396.60 · 23 records | Novo Nordisk Inc | BREZTRI, Cologuard Collection Kit, ELIQUIS, FARXIGA, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, SAPIEN 3 Ultra RESILIA, The Cologuard Plus Collection Kit, Wegovy, ZAVZPRET, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error